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Summary
Recent studies suggest that thousands of genes may contribute to breast cancer pathophysiologies when deregulated by
genomic or epigenomic events. Here, we describe a model ‘‘system’’ to appraise the functional contributions of these genes
to breast cancer subsets. In general, the recurrent genomic and transcriptional characteristics of 51 breast cancer cell lines
mirror those of 145 primary breast tumors, although some significant differences are documented. The cell lines that com-
prise the system also exhibit the substantial genomic, transcriptional, and biological heterogeneity found in primary tumors.
We show, using Trastuzumab (Herceptin) monotherapy as an example, that the system can be used to identify molecular
features that predict or indicate response to targeted therapies or other physiological perturbations.Introduction
The evolution of a normal, finite-life-span somatic epithelial cell
into an immortalized, metastatic cell requires deregulation of
multiple cellular processes including genome stability, prolifera-
tion, apoptosis, motility, and angiogenesis (Albertson et al.,
2003; Hanahan and Weinberg, 2000). Changes in genome
copy number and/or structure are particularly important as de-
regulating events in cancer progression (Hyman et al., 2002; Jef-
frey et al., 2005; Kallioniemi et al., 1994; Loo et al., 2004; Pollack
et al., 2002; Roylance et al., 1999; Tirkkonen et al., 1998), and
elucidation of recurrent aberrations has revealed many impor-
tant oncogenes and tumor suppressors (Neve et al., 2004). In
fact, over a thousand genes have now been reported to be de-
regulated by recurrent genome aberrations in breast cancer
alone (Fridlyand et al., 2006; Hyman et al., 2002; Pollack et al.,CANCER CELL 10, 515–527, DECEMBER 2006 ª2006 ELSEVIER INC. D2002). Functional assessment of several of these genes in cell
lines and xenografts has provided invaluable insights into the
roles they play in cellular physiology (Alimandi et al., 1995;
Cheng et al., 2004). However, interpreting these results in the
context of breast cancer pathophysiology requires an under-
standing of the extent to which the cell lines mirror aberrations
that are present in primary tumors. To this end, we describe
here a comprehensive comparison of the molecular and biolog-
ical features of a collection of 51 breast cancer cell lines with
those measured for primary breast tumors.
The central result of the study is a comparison of genome
copy number and transcriptional profiles for the cell lines with
those measured for primary breast tumors (Fridlyand et al.,
2006). We also evaluated protein and phosphoprotein levels
for selected genes in signaling pathways that are frequently de-
regulated in cancer. These analyses show that the cell linesS I G N I F I C A N C E
The description of the in vitro breast cancer cell line system described here allows assessment of similarities and differences between
the cell lines and primary human breast tumors. In general, the system seems well suited to assess the functional contributions of ge-
nome copy number abnormalities to breast cancer pathophysiologies, sincemost of the recurrent genomic deregulation of transcrip-
tion present in primary tumors is retained in the cell lines. The genomically and biologically heterogeneous cell line systemalsomay be
used to identify molecular features that predict or indicate response (or lack thereof) to pathway-targeted therapeutic agents. These
features may be assessed as candidate response predictors/indicators to guide early-phase clinical trials.OI 10.1016/j.ccr.2006.10.008 515
A R T I C L Edisplay the same heterogeneity in copy number and expression
abnormalities as the primary tumors, and they carry almost all of
the recurrent genomic abnormalities associated with clinical
outcome in primary tumors. In addition, the breast cancer cell
lines cluster into basal-like and luminal expression subsets, as
do primary tumors, although the partitioning of genome aberra-
tions between these subsets is somewhat different than that in
basal-like and luminal primary tumors. Importantly, the cell line
collection exhibits heterogeneous responses to targeted thera-
peutics paralleling clinical observations. From these studies, we
conclude that the cell line collection mirrors most of the impor-
tant genomic and resulting transcriptional abnormalities found
in primary breast tumors and that analysis of the functions of
these genes in the ensemble of cell lines will accurately reflect
how they contribute to breast cancer pathophysiologies. We
also illustrate the possibility that correlative analyses of the
heterogeneous responses to treatment with therapeutic agents
that attack these genes may allow identification of molecular
features that predict response in individual patients.
Results
Genomic features
We performed array CGH using arrays at 1 Mb resolution (see
Experimental Procedures). Our analyses of genome copy num-
ber abnormalities in 51 cell lines (listed in Table 1) are provided in
Table S1 in the Supplemental Data available with this article on-
line (see also http://cancer.lbl.gov/breastcancer/data.php). As
with primary tumors, cell lines exhibit pronounced genomic het-
erogeneity, even between lines with similar transcriptional pro-
files (e.g., luminal or basal-like) and biological characteristics, al-
though the number of genome abnormalities per cell line is, on
average, higher than that in primary tumors. Figure S1 shows
genome copy number abnormality profiles for cell lines that ex-
hibit different levels of genome aberration complexity, in agree-
ment with published array CGH for these cell lines (Larramendy
et al., 2000; Shadeo and Lam, 2006; Snijders et al., 2001). Sev-
eral, like SUM159PT, show relatively few abnormalities. Others,
like T47D, show many low-level abnormalities, and many, like
BT474 and MCF7, show many abnormalities with high-level
amplification. A few, like HCC1500, show extraordinary levels
of abnormality not typically found in primary tumors.
Figures 1A and 1B show that the recurrent abnormalities in the
cell lines are similar to those in primary tumors, indicating that
cell lines have retained most of the genomic abnormalities of
the original tumors including regions of high-level amplification,
and they have not selected abundant new abnormalities. Recur-
rent gene copy number changes in the 51 breast cancer cell
lines that match recurrent aberrations in primary tumors are
summarized in Figure S2. However, the agreement is not per-
fect, as illustrated in the comparisons of the relative frequencies
of gains and losses between tumors and cell lines shown in Fig-
ures 1C and 1D, respectively. The major differences involve los-
ses of chromosome 5q (more frequent in tumors) and chromo-
some 18 (more frequent in cell lines). The direct comparison of
the cell line genome copy number aberration profiles with those
in 145 primary tumors in Figure 2 shows that the cell line collec-
tion is overrepresented in lines with high-level amplification (i.e.,
in the previously reported ‘‘amplifier’’ genotype [Fridlyand et al.,
2006]).516Transcription profiles
Hierarchical clustering of our analyses of transcriptional profiles
(Table S2; see also http://cancer.lbl.gov/breastcancer/data.
php) of the 51 breast cell lines using transcripts showing sub-
stantial variation across the samples revealed two major
branches (Figure 3A). We identified one cluster as luminal
[ERBB3- and ESR1-positive, (ii) and (i) in Figure 3A] and the other
as basal-like [ESR1-negative, CAV1-positive, (iii) in Figure 3A;
Jones et al., 2004] using published gene markers of in vivo his-
tology (Abd El-Rehim et al., 2004; Cattoretti et al., 1988; Jones
et al., 2004; Korsching et al., 2002; Nielsen et al., 2004; Simpson
et al., 2004). The luminal cluster was generally uniform across
all samples, whereas the basal-like cluster contained at least
two major subdivisions we termed Basal ‘‘A’’ [KRT5-, KRT14-
positive, (v) in Figure 3A] and Basal ‘‘B’’ [VIM-positive, (iv) in
Figure 3A]. The Basal A cluster matches closely to the Perou
basal-like signature (Chung et al., 2002; Perou et al., 1999,
2000; Sorlie et al., 2001), whereas themore distinct Basal B sub-
group exhibits a stem-cell like expression profile andmay reflect
the clinical ‘‘triple-negative’’ tumor type. These clusters and his-
tological associations are similar to those previously reported for
tumors and cell lines (Chung et al., 2002; Perou et al., 1999,
2000; Sorlie et al., 2001), and clustering of the cell lines using
gene expression of published markers of histology (Figure S3A)
produced a cluster similar to those in Figure 3.
To identify genes that classify the luminal, Basal A, and Basal
B subtypes, PAM analysis was performed (see Experimental
Procedures) (Tibshirani et al., 2002). Table S3 lists 305 classifier
genes, and Figure 3B shows the breast cancer cell lines clus-
tered by those genes. These genes are likely to be intimately in-
volved in the differentiation status of the cell types and/or tumor
biology.
In addition to published histological markers, luminal A cell
lines also preferentially expressed genes, such as GATA3,
TOB1, ERBB3, and SPDEF, that have been associated with
a more differentiated, noninvasive phenotype (Beck et al.,
2001; Charafe-Jauffret et al., 2006; Feldman et al., 2003; Lim
et al., 2000). Basal B cell lines were more clearly distinct from lu-
minal cells than those in the Basal A cluster and preferentially
expressed genes such as CD44, MSN, TGFBR2, CAV1/2, VIM,
SPARC, and AXL, while CD24 was weakly expressed. Interest-
ingly, MCF10A andMCF12A (two immortal, nontransformed cell
lines) share transcriptional characteristics with all other identi-
fied subtypes and had many features of basal progenitor cells
(Dontu et al., 2003a; Stingl et al., 1998), suggesting that these
cells may represent a multipotent lineage. In contrast to Perou
et al. (2000), we did not find a distinct HER2 cluster. Rather,
HER2-amplified cells were scattered across the luminal cluster
and the Basal A cluster.
Although the gene expression patterns generally reflected the
major transcriptional classes found in primary tumors, the differ-
ences in frequency of genome copy number abnormalities be-
tween basal-like and luminal cell lines were different than those
between luminal and basal-like primary tumors (Fridlyand et al.,
2006). For example, luminal tumors (Figure 4A) showed fewer
genome aberrations than basal tumors (Figure 4B) overall, and
basal-like tumors carried higher frequencies of copy number
gains involving chromosomes 10p and 22q and losses of 5q,
12q, and 15p compared to luminal tumors (Figure 4C). However,
luminal cell lines (Figure 4D) showed about the same frequency
of genome copy number abnormalities as basal-like cell linesCANCER CELL DECEMBER 2006
A R T I C L ETable 1. Source, clinical, and pathological features of tumors used to derive breast cancer cell lines used in this study
Cell line Gene cluster ER PR HER2 TP53 Source Tumor type Age (years) Ethnicity Culture media Culture conditions
1 600MPE Lu + [2] 2 IDC DMEM, 10% FBS 37C, 5% CO2
2 AU565a Lu 2 [2] + +WT PE AC 43 W RPMI, 10% FBS 37C, 5% CO2
3 BT20 BaA 2 [2] ++WT P.Br IDC 74 W DMEM, 10% FBS 37C, 5% CO2
4 BT474 Lu + [+] + + P.Br IDC 60 W RPMI, 10% FBS 37C, 5% CO2
5 BT483 Lu + [+] 2 P.Br IDC, pap 23 W RPMI, 10% FBS 37C, 5% CO2
6 BT549 BaB 2 [2] ++M P.Br IDC, pap 72 W RPMI, 10% FBS 37C, 5% CO2
7 CAMA1 Lu + [2] + PE AC 51 W DMEM, 10% FBS 37C, 5% CO2
8 HBL100 BaB 2 [2] ++ P.Br N 27 DMEM, 10% FBS 37C, 5% CO2
9 HCC1007d Lu + [2] [+/2] P.Br Duc.Ca 67 B RPMI, 10% FBS 37C, 5% CO2
10 HCC1143d BaA 2 [2] ++M P.Br Duc.Ca 52 W RPMI, 10% FBS 37C, 5% CO2
11 HCC1187d BaA 2 [2] ++M P.Br Duc.Ca 41 W RPMI, 10% FBS 37C, 5% CO2
12 HCC1428d Lu + [+] [+] PE AC 49 W RPMI, 10% FBS 37C, 5% CO2
13 HCC1500d BaB 2 [2] 2 P.Br Duc.Ca 32 B RPMI, 10% FBS 37C, 5% CO2
14 HCC1569d BaA 2 [2] + 2M P.Br MC 70 B RPMI, 10% FBS 37C, 5% CO2
15 HCC1937d BaA 2 [2] [2] P.Br Duc.Ca 24 W RPMI, 10% FBS 37C, 5% CO2
16 HCC1954d BaA 2 [2] + [+/2] P.Br Duc.Ca 61 EI RPMI, 10% FBS 37C, 5% CO2
17 HCC202d Lu 2 [2] + [2] P.Br Duc.Ca 82 W RPMI, 10% FBS 37C, 5% CO2
18 HCC2157d BaA 2 [2] [+] P.Br Duc.Ca 48 B RPMI, 10% FBS 37C, 5% CO2
19 HCC2185d Lu 2 [2] [+] PE MLCa 49 WH RPMI, 10% FBS 37C, 5% CO2
20 HCC3153d BaA 2 [2] [2] RPMI, 10% FBS 37C, 5% CO2
21 HCC38d BaB 2 [2] ++M P.Br Duc.Ca 50 W RPMI, 10% FBS 37C, 5% CO2
22 HCC70d BaA 2 [2] ++M P.Br Duc.Ca 49 B RPMI, 10% FBS 37C, 5% CO2
23 HS578T BaB 2 [2] +M P.Br IDC 74 W DMEM, 10% FBS 37C, 5% CO2
24 LY2 Lu + [2] +/2 PE IDC 69 W DMEM, 10% FBS 37C, 5% CO2
25 MCF10Ab BaB 2 [2] +/2WT P.Br F 36 W DMEM/F12* 37C, 5% CO2
26 MCF12Ab BaB 2 [2] + P.Br F 60 W DMEM/F12* 37C, 5% CO2
27 MCF7 Lu + [+] +/2WT PE IDC 69 W DMEM, 10% FBS 37C, 5% CO2
28 MDAMB134VI Lu + [2] +/2WT PE IDC 47 W DMEM, 10% FBS 37C, 5% CO2
29 MDAMB157 BaB 2 [2] 2 PE MC 44 B DMEM, 10% FBS 37C, 5% CO2
30 MDAMB175VII Lu + [2] +/2WT PE IDC 56 B DMEM, 10% FBS 37C, 5% CO2
31 MDAMB231 BaB 2 [2] ++M PE AC 51 W DMEM, 10% FBS 37C, 5% CO2
32 MDAMB361 Lu + [2] + 2WT P.Br AC 40 W DMEM, 10% FBS 37C, 5% CO2
33 MDAMB415 Lu + [2] + PE AC 38 W DMEM, 10% FBS 37C, 5% CO2
34 MDAMB435 BaB 2 [2] +M PE IDC 31 W DMEM, 10% FBS 37C, 5% CO2
35 MDAMB436 BaB [2] [2] [2] PE IDC 43 W L15, 10% FBS 37C, no CO2
36 MDAMB453 Lu 2 [2] 2WT PF AC 48 W DMEM, 10% FBS 37C, 5% CO2
37 MDAMB468 BaA [2] [2] [+] PE AC 51 B L15, 10% FBS 37C, no CO2
38 SKBR3a Lu 2 [2] + + PE AC 43 W McCoys 5A, 10% FBS 37C, 5% CO2
39 SUM1315MO2c BaB 2 [2] [+] Sk IDC Ham’s F12, 5%-IE 37C, 5% CO2
40 SUM149PTc BaB [2] [2] [+] P.Br Inf Duc.Ca Ham’s F12, 5%-IH 37C, 5% CO2
41 SUM159PTc BaB [2] [2] [2] P.Br AnCar Ham’s F12, 5%-IH 37C, 5% CO2
42 SUM185PEc Lu [2] [2] [2] PE Duc.Ca Ham’s F12, 5%-IH 37C, 5% CO2
43 SUM190PTc BaA 2 [2] + [+/2] P.Br Inf Ham’s F12, SF-IH** 37C, 5% CO2
44 SUM225CWNc BaA 2 [2] + ++ CWN IDC Ham’s F12, 5%-IH 37C, 5% CO2
45 SUM44PEc Lu [+] [2] [2] PE Ca Ham’s F12, SF-IH** 37C, 5% CO2
46 SUM52PEc Lu [+] [2] [2] PE Ca Ham’s F12, 5%-IH*** 37C, 5% CO2
47 T47D Lu + [+] ++M PE IDC 54 RPMI, 10% FBS 37C, 5% CO2
48 UACC812 Lu + [2] + 2WT P.Br IDC 43 DMEM, 10% FBS 37C, 5% CO2
49 ZR751 Lu + [2] 2 AF IDC 63 W RPMI, 10% FBS 37C, 5% CO2
50 ZR7530 Lu + [2] + 2WT AF IDC 47 B RPMI, 10% FBS 37C, 5% CO2
51 ZR75B Lu + [2] +/2 RPMI, 10% FBS 37C, 5% CO2
AC, adenocarcinoma; AF, ascites fluid; AnCa, anaplastic carcinoma; ASC, acantholytic squamous carcinoma; BaA, Basal A; BaB, Basal B; Ca, carcinoma;
CWN, chest wall nodule; Duc.Ca, ductal carcinoma; F, fibrocystic disease; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; Inf, inflammatory;
LN, lymph node; Lu, luminal; MC, metaplastic carcinoma; MLCa, metastatic lobular carcinoma; N, normal; Pap, papillary; ND, not done; P.Br, primary breast;
PE, pleural effusion; Sk, skin; W, White; B, Black; H, Hispanic; EI; East Indian.
ER/PR/HER2/TP53 status: ER/PR positivity, HER2 overexpression, and TP53 protein levels and mutational status (obtained from the Sanger web site; M, mutant
protein; WT, wild-type protein) are indicated. Expression data are derived from mRNA and protein levels presented in this article (Table S2 and Figure S4).
Square brackets indicate that levels are inferred from mRNA levels alone where protein data is not available.
Media conditions: FBS, fetal bovine serum; I, Insulin (0.01 mg/ml); H, hydrocortisone (500 ng/ml); E, EGF (20 ng/ml); DMEM, Dulbecco’s modified Eagle’s me-
dium, GIBCO #11965-092; RPMI, RPMI medium 1640, GIBCO #27016-021; Ham’s F12, F-12 nutrient mixture (Ham), GIBCO #11039-021; DMEM/F12, Dulbecco’s
modified Eagle’s medium: Nutrient mix F-12 (D-MEM/F-12), GIBCO #11039-021; L15, Leibovitz’s L-15 medium, GIBCO #11415-064. *For MCF10A and MCF12A,
supplement DMEM/F12 media with 5% horse serum, 20 ng/ml EGF, 100 ng/ml cholera toxin, 0.01 mg/ml insulin, and 500 ng/ml hydrocortisone. **For serum-free
(SF) medium, supplement Ham’s F12 with 0.5 mg/ml bovine serum albumin, 5 mM ethanolamine, 10 mM HEPES, 5 mg/ml transferrin, 10 mM T3, 50 mM Se, 5 mg/ml
insulin, 1 mg/ml hydrocortisone. ***For serum-containing F12 media, supplement media with 5% FBS, 5 mg/ml insulin, and 1 mg/ml hydrocortisone or 10 ng/ml
EGF.
aAU565 and SKBR3 were derived from the same patient.
bDerived from a reduction mammoplasty.
cProvided by Steve Ethier (http://www.cancer.med.umich.edu/breast_cell/Production/index.html).
dProvided by Adi Gazdar, now available through ATCC (Gazdar et al., 1998).CANCER CELL DECEMBER 2006 517
A R T I C L EFigure 1. Comparison of array CGH analyses
of human breast cancer cell lines and primary
tumors
A and B: Frequencies of significant increases or
decreases in genome copy number are plotted
as a function of genome location for 51 cell lines
(A) and 145 primary tumors (Fridlyand et al.,
2006) (B). Positive values indicate frequencies
of samples showing copy number increases
[Log2(copy number) > 0.3], and negative values
indicate frequencies of samples showing copy
number decreases [Log2(copy number) <20.3].
C and D: Differences (y axis) between frequen-
cies of gains and losses across the genome for
the cell lines versus the tumors are represented
in C and D, respectively. Genome copy number
aberration frequencies are plotted as a function
of location position in the genome beginning at
1pter to the left and ending at Xqter to the right
(chromosome locations are indicated by num-
bers above and below graphs). Vertical lines
indicate chromosome boundaries. Vertical dot-
ted lines indicate centromere locations.(Figure 4E). In addition, luminal cell lines showed more copy
number gains involving chromosomes 12q and fewer copy num-
ber gains involving 19p relative to basal-like cell lines (Figure 4F).
Genomic deregulation of gene expression
Our analyses of gene expression and copy number in the 51 cell
lines revealed 1778 gene transcripts whose levels were corre-
lated with genome copy number (Pearson’s correlation R 0.5,
Holm-adjusted p value % 0.05), suggesting that expression
levels were deregulated by genomic aberrations. Table S4
summarizes the statistically significant genome copy number
versus gene expression correlations discovered in this study.
A similar analysis in primary breast tumors (Fridlyand et al.,
2006) identified 1182 significantly correlated genes (Pearson’s
correlationR 0.5, Holm-adjusted p value% 0.05). We assessed
the agreement between the tumor and cell line correlation data
sets and found that 72% of the genes scored as significantly
deregulated in primary tumors also were significantly deregu-
lated in the cell line set (odds ratio for agreement of 16 for cor-
relation > 0.7). This indicates that the cell lines retain most of
the genome-aberration-mediated gene deregulation present in
primary tumors (Table S4).
Sixty-six of the deregulated genes in the tumors were in re-
gions of high-level amplification associated with reduced sur-
vival duration and so are both markers for tumors that are resis-
tant to current therapies and candidate therapeutic targets. We
identified cell lines in which the 66 candidate therapeutic target
genes were amplified and overexpressed by clustering the cell
lines using probe sets matched to these genes. Figure 5518indicates the cell lines in which these genes are amplified and
overexpressed. Combined, these data show that 88% (55/66)
of these genes are amplified and overexpressed in at least
one cell line. These cell lines should be useful models for assess-
ment of the roles that gene amplification and overexpression
play in breast cancer pathophysiology.
Protein profiles
We measured levels of 49 gene products or posttranslationally
modified gene products associated with aspects of signal trans-
duction and cell cycle regulation and/or frequently found to be
aberrant in human cancers using western analysis. These anal-
yses revealed cell lines in which these regulatory processesmay
be aberrant and allowed an initial assessment of the extent to
which genome aberrations affected the protein/phosphoprotein
levels. These data also allowed us to assess the extent to which
the RNA levels in the cell lines reflected protein levels. Western
blots for the cell line collection are shown in Figure S4, and semi-
quantitative measures of protein levels are summarized in Table
S5. Figures S3B and S3C show that the degree of concordance
between semiquantitative measures of protein levels from the
western blots and RNA expression levels from the Affymetrix ex-
pression array analyses varied considerably among the genes
(Souchelnytskyi, 2002). We found that concordance for 54%
was strong (e.g., ESR1, CDKN1B), while 46% showed low or
no concordance (e.g., PTEN). This finding is not surprising con-
sidering the high degree of posttranslational processing and
degradation that occurs in signaling pathways that regulate pro-
liferation and survival.CANCER CELL DECEMBER 2006
A R T I C L EFigure 2. Unsupervised hierarchical clustering of
genome aberrations in 51 breast cancer cell
lines and 145 primary breast tumors
Clusters show results at 1952 BAC probes com-
mon between the tumor and cell line CGH ar-
rays. Each row represents a BAC probe, and
each column represents a cell line or tumor sam-
ple. Green indicates increased genome copy
number, and red indicates decreased genome
copy number. Yellow indicates high-level ampli-
fication. The bar to the left shows chromosome
locations with chromosome 1pter to the top
and 22qter to the bottom. The locations of the
odd-numbered chromosomes (shaded black)
are indicated. The upper color bar shows col-
umns representing tumors or cell lines. The lower
color bar indicates the genomic characteristics
of the cell lines and tumors from this study and
for the tumors as reported (Fridlyand et al.,
2006). Color codes are indicated at the bottom
of the figure.Biological and molecular associations
One important use of the cell line collection is identification of
molecular events that are associated with biological phenotype.
Establishing such associations is a first step in the development
of a molecular understanding of the biological phenotype. The
molecular diversity between the cell lines allows this to be ac-
complished in a robust manner.
Morphology and invasion
One of the clearest associations in the cell line collection is the
relationship between the transcriptionally defined subgroups
and distinctive biological characteristics such as morphology
and invasive potential illustrated in Figure 6. Figure 6A shows
that luminal cells appear more differentiated and form tight
cell-cell junctions, while the Basal B cells appear less differenti-
ated and have a more mesenchymal-like appearance. Basal ACANCER CELL DECEMBER 2006cells may have either luminal-like or basal-like morphologies.
Similar stratification was noted in three-dimensional cultures
(data not shown). Figure 6B shows that Basal B cells are much
more frequently highly invasive in Boyden chamber assays
than Basal A and luminal cells.
Predictors of therapeutic response
One of the promising potential applications of association anal-
ysis using the cell line system is identification of molecular sig-
natures that predict responses to therapies that target genes
that are deregulated by genome abnormalities. To illustrate this
application, we assessed biological responses to Trastuzumab
in nine HER2-amplified cell lines and two control cell lines.
Genome copy number profiles for the HER2-amplified cell
lines are shown in Figure 7A. Figure 7B shows that the non-
amplified control cell lines, MCF7 and T47D, were unaffected519
A R T I C L EFigure 3. Gene expression profiles of 51 human breast cancer cell lines
A: Hierarchical cluster analysis of breast cancer cell lines with subclusters [(i)
through (v)] indicated by colored bars at side. Genes were restricted to
those showing significant variance across all samples, resulting in clustering
of 1438 probe sets (see Experimental Procedures).
B:Cell lines clustered by genes selected by PAM analysis representing the lu-
minal, Basal A, and Basal B clusters. Clustering was performed as described
in the Experimental Procedures. Each row represents a gene, and each
column represents a cell line sample. As shown in the color bar, black
represents no change, red represents upregulation, and green represents
downregulation of gene expression.520by Trastuzumab as expected. However, this figure also shows
that only three of the nine HER2-amplified lines exhibited a
robust response to Trastuzumab as measured by inhibition of
BrdUrd incorporation. This frequency of response is similar
to that reported in clinical evaluations of Trastuzumab mono-
therapy (Vogel et al., 2005). Pearson’s correlations between
molecular signatures and biological response to Trastuzumab
in HER2-amplified cell lines revealed associations with Trastu-
zumab response. These are summarized in Table S6. Protein
levels most strongly correlated with response included in-
creased levels of MEK (S217/219), ESR1, TYK2, FASN, GRB7,
and MAPK1/3 (Thr202/Tyr204). Protein levels associated with
resistance included high levels of SFN, CAV2, GRB2, RB1,
and FLNA. Genomic regions 12q13 and 19q13 were correlated
with sensitivity, while 1p36, 11q14, and 17p11 were associated
with resistance. From ontologic analysis of gene expression, it
appears that upregulation of genes involved in insulin/MAPK
signaling predicts response to Herceptin, whereas the mTOR
pathway, Toll-like receptor pathway, N-Glycan biosynthesis,
and inositol-phosphate signaling are associated with resis-
tance. This analysis suggests that assessment of these molec-
ular features in primary tumors will more precisely identify
patients that will respond to Trastuzumab.
Indicators of therapeutic response
Association studies also identify molecular events that change
in response to treatment with targeted therapies. A previous
study suggested that regulation of p27KIP1 is critical in mediating
response to Trastuzumab (Nahta et al., 2004). However, this
study was limited to clonal Trastuzumab-resistant variants of
SKBR3 cells. Our analyses of the molecular and biological re-
sponses of HER2 amplified cell lines to Trastuzumab, shown
in Figures 7B and 7C (or to 4D5; data not shown), confirm that
association. Specifically, we found that increases in the levels
of p27KIP1 (CDKN1B) protein and translocation of p27KIP1 to
the nucleus were associated with cell cycle arrest as measured
by inhibition of BrdUrd incorporation—probably due to inhibition
of the formation of CCNE1-CDK2 complexes (Lane et al., 2000;
Nahta et al., 2004; Neve et al., 2000). Importantly, while the
steady-state level of p27KIP1 tended to be lower in Trastuzumab-
responsive cell lines, it was not significantly predictive of overall
response. These analyses suggest that measurement of the
nuclear localization p27KIP1 in clinical specimens (e.g., in fine
needle aspirates or core biopsies) taken during early stages
of treatment with Trastuzumab will be an early indication that
patients are responding to the treatment.
Discussion
Breast cancer is a remarkably heterogeneous disease, but sub-
sets of tumors show recurrent patterns of transcriptional, geno-
mic, and biological abnormality. Understanding how genes in
these ‘‘patterns’’ collectively function in an otherwise heteroge-
neous biological setting to enable progression and modulate re-
sponse to therapy is critical to improving management of the
disease. Association studies in primary tumors provide clues
about molecular events that may be important in cancer patho-
physiology, but more formal proof requires model systems that
mirror both the heterogeneity and recurrent molecular aberra-
tions found in primary tumors and that can be manipulated to
test associations. The comparisons between cell lines and pri-
mary tumors in this study show that the cell line collection, asCANCER CELL DECEMBER 2006
A R T I C L EFigure 4. Comparative analyses of aberration frequencies in basal and luminal primary tumors and cell lines
A–C: A and B show frequencies of genome copy number gains and losses in luminal and basal breast tumors, respectively (Fridlyand et al., 2006). C shows
univariate statistical assessments of differences between the two tumor types.
D–F: D and E show frequencies of genome copy number gains and losses in luminal and Basal B breast cancer cell lines, respectively. F shows univariate sta-
tistical assessments of differences between the two cell line types. p values of 0.05 and 0.01 are indicated as in C. All data are plotted beginning at chromo-
some 1pter to the left and ending at Xqter to the right. Vertical solid lines indicate chromosome boundaries. Vertical dashed lines indicate centromere loca-
tions. p values of 0.05 and 0.01 are indicated by dashed horizontal lines in C and F.a system, mirrors many but not all of the biological and genomic
properties of primary tumors.
In general, the cell lines mirror both the genomic heterogene-
ity (Figure S1) and the recurrent genome copy number abnor-
malities found in primary tumors with high fidelity (Figures 1
and 2). This is remarkable, considering the fact that many of
the cell lines have been carried in culture for many years or de-
cades. This indicates that they have not accumulated substan-
tial new recurrent aberrations during extended culture and is
supported by our own analysis showing stable genomic and
expression patterns in the cell lines over multiple passages.
In addition, important genome aberration ‘‘landmarks’’ like
the high-level amplifications associated with poor outcome in
primary tumors are well represented. That said, the cell lines
carry more aberrations, on average, than primary tumors, and
high-level amplification is more frequent in the cell lines, while
cell lines with simple ‘‘1q/16’’ genotypes (Fridlyand et al.,
2006) are missing in the cell line collection (Figure 2). This might
be explained by the fact that the cell lines have been derived
predominantly from late-stage tumors or pleural effusions,
while the tumors against which they were compared were
predominantly early stage (Fridlyand et al., 2006). Alternately,
high-level amplification may provide a selective advantage for
growth in vitro, so cell lines with high-level amplification were
isolated preferentially. The associations between gene expres-
sion and copy number in primary tumors are mostly preserved
in the cell lines, although the number of genes showing signif-
icant associations with copy number is greater in the cell lines
than in primary tumors. The increased number of significant as-
sociations in the cell lines may be because the cell cultures are
not contaminated by normal epithelial or nonepithelial cells that
may introduce confounding expression patterns, thereby de-
creasing some associations to the point where they are no lon-
ger significant. Overall, however, these data argue that the
roles in breast cancer pathophysiology of genome aberrations
captured in the cell line collection can be elucidated byCANCER CELL DECEMBER 2006manipulating the expression levels of deregulated genes in
the cell lines.
However, some aspects of primary tumor cancer genomics
will be difficult to study using the current collection. For exam-
ple, additional cell lines derived from early-stage breast cancers
will be needed to study aberration patterns such as the ‘‘1q/
16q’’ breast tumor subtype. This may require development of
cell culture conditions that are permissive to the growth of these
cells. It is noteworthy in this context that the HCC cell lines (Gaz-
dar et al., 1998; Larramendy et al., 2000) preferentially populate
the basal-like lineage, while other cell lines (e.g., the SUM cells
[Ethier et al., 1993]) are represented across all the lineage sub-
types. This suggests the possibility that culture conditions
may bias selection of breast tumor subtypes. Alternatively, the
laboratory-specific lineage dependence of the derived cell lines
may be explained by the tissue origin. For example, the HCC cell
lines were typically derived from primary breast tumors, while
many of the other cell lines were derived from pleural effusions
(Table 1).
Other aspects of cancer biology also are more or less accu-
rately represented by the cell line system. For example, the
cell lines can be classified into luminal and basal-like subtypes
as found in primary tumors (Figure 3). However, the two luminal
subsets evident in tumors are not apparent in the cell lines, and
the basal-like cell lines resolve into two distinctive clusters
(Basal A and Basal B) that are not apparent in analyses of pri-
mary tumors. Similar discrepancies have been noted in earlier
studies (Perou et al., 1999). Again, this might be due to the
fact that the cell line expression profiles are not ‘‘contaminated’’
with normal epithelial or stromal cells so that the clusters resolve
more clearly in the cell lines, or that the differences are due to the
absence of stromal or physiological interactions and/or signal-
ing in cell culture (Kuperwasser et al., 2004; Radisky and Bissell,
2004). Arguing against this, however, is our observation that the
differences between the genome aberration patterns for the
basal-like and luminal clusters in the cell line systemdon’tmatch521
A R T I C L EFigure 5. A functional model to investigate lead candidate therapeutic targets
Gene expression and copy number for the 66 candidate therapeutic genes in the 51 breast cancer cell lines. Genes were selected for their overexpression
and association with outcome in human breast tumors (Chin et al., 2006). High gene expression (R2-fold over mean gene expression for all the samples) is
shown in red, and high-level amplification (R0.9 Log2 ratio) is shown in yellow for each cell line. Genes that have high expression and gene copy number
are shown in blue. Gene HUGO names are shown to the right, and the corresponding BAC clone ID and chromosome are shown to the left.differences in these subtypes in primary tumors (Figure 4). This
suggests that the cell lines may be derived from subpopulations
of tumor cells that are selected because they grow well. Intrigu-
ingly, in this regard, the highly invasive Basal B cells carry the
CD44+/CD242/low phenotype associated with the subpopula-
tion of tumorigenic stem cells recently identified in breast cancer
(Al-Hajj et al., 2003; Dontu et al., 2003b).
The high fidelity to which genome-aberration-induced tran-
scriptional changes are preserved in the cell lines and the exis-
tence of substantial genomic, transcriptional, translational, and
biological heterogeneity in the overall system support the idea522that assessment of responses to inhibitors of the resulting dom-
inant or dominant-negative genes will reveal molecular events
that predict response/resistance. This concept is supported by
studies of responses to Iressa of lung cancer cell lines (Tracy
et al., 2004; Zhao et al., 2004) and leukemia cells (Carter et al.,
2005; Mahon et al., 2000). Our analyses of the subset of HER2-
amplified breast cancer cell lines show variable response to
treatment with Trastuzumab as observed in the clinical trials
(Vogel et al., 2001) and identifymolecular features thatmay allow
more precise identification of HER2-positive patients that will
respond to therapeutic protocols containing Trastuzumab.CANCER CELL DECEMBER 2006
A R T I C L EFigure 6. Relationship of transcriptional profiles to biological function
A: Morphology of cell lines grown in tissue culture on plastic.
B: Invasive potential of 30 breast cancer cell lines as measured by modified Boyden chamber assays (see Experimental Procedures). Each data point repre-
sents the mean 6 SD of three wells.Specifically, increased protein levels of ESR1, TYK2, FASN,
GRB7, MEK (S217/219), and MAPK1/3 (Thr202/Tyr204) predict
Trastuzumab sensitivity, whereas increased SFN, CAV2,
GRB2, RB1, and FLNA expression is associated with Trastuzu-
mab resistance. Many of these genes are known signaling tar-
gets or signal integrators of HER2 (Hynes and Lane, 2005), and
its downstreampathways, PI3KandMAPK; therefore,mutations
in these pathways may be responsible for loss of HER2 onco-
gene ‘‘addiction’’ and may modulate therapeutic response. In
support of this, gene expression profiles indicate that increased
expression of several insulin/MAPK pathway genes predicts re-
sponse, whereas increased mTOR, Toll-like receptor, N-Glycan
biosynthesis, and inositol-phosphate signaling predicts resis-
tance. These and subsequent studies set the stage for detailed
study of mechanisms of resistance, development of markers
that predict or indicate response, and potential new therapeutic
targets.
In sum, we have cataloged the genomic and molecular prop-
erties of a panel of cell lines and demonstrated a fidelity to those
found in primary breast tumors. Recurrent genome aberrations
and the resulting transcriptional changes are well preserved inCANCER CELL DECEMBER 2006the cell line collection. Thus, the cell lines seemwell suited to as-
sessment of the functional consequences of genome-aberra-
tion-mediated gene deregulation and to identification of molec-
ular features that predict resistance/sensitivity to agents that
target these aberrations. Continuing characterization of these
cell lines, development of more cell lines and more realistic
cell culture environments, and assessment of multiple aberra-
tion-targeted agents should provide an increasingly useful re-
source for the assessment of how genome aberrations contrib-
ute to breast cancer pathophysiology. This will facilitate our
understanding of the mechanisms of tumorigenesis and stimu-
late development of new therapies targeted to selectively inter-
fere with one or more of these processes.
Experimental procedures
Cell culture
Breast cancer cell lines were obtained from the ATCC or from collections de-
veloped in the laboratories of Drs. Steve Ethier and Adi Gazdar. Cell lines
were obtained from these sources to avoid errors that occur when obtaining
lines through ‘‘secondhand’’ sources. Since we acknowledge the existence523
A R T I C L EFigure 7. Indicators of therapeutic response to Trastuzumab in HER2-positive breast cancer cell lines
A: CGH profiles of nine breast cancer cell lines overexpressing HER2.
B: Response of HER2-overexpressing cell lines to 48 hr treatment with 21 mg/ml Trastuzumab (Herceptin) as measured by BrdUrd incorporation (top panel) and
relocalization of p27KIP1 (lower panel).of multiple clonal variants of some cell lines throughout the scientific commu-
nity, all results presented here are reflective of the cell lines we have in our
collection. To maintain the collections’ integrity, cell lines have been carefully
maintained in culture, and stocks of the earliest-passage cells have been
stored. Quality control is maintained by careful analysis and reanalysis of
morphology, growth rates, gene expression, and protein levels. Cell lines
can be accurately identified by CGH analysis. All extracts were made from
subconfluent cells in the exponential phase of growth in full media. Informa-
tion about the biological characteristics of the cell lines and the culture con-




Cells growing exponentially in culture were washed in phosphate buffered
saline (PBS), pelleted by centrifugation, resuspended in PBS, and pelleted
again. Pellets were either frozen for long-term storage or used to extract ge-
nomic DNA directly. Genomic DNA was extracted using the Wizard DNA Pu-
rification Kit (Promega), further purified with a phenol/chloroform extraction,
and quantified using a fluorimeter. Phenol/chloroform extraction of the result-
ing DNA increased measurement precision significantly in some experi-
ments, presumably by removing proteins that interfered with DNA labeling
and hybridization.
RNA isolation
Total RNA was extracted from cell lines using Trizol, according to standard
protocols (Invitrogen). RNA integrity was assessed by denaturing formalde-
hyde agarose gel electrophoresis or by microanalysis (Agilent Bioanalyzer,
Palo Alto, CA).524Cell lysates
Protein lysates were prepared from cells at 50%–75% confluency. The cells
were washed in ice-cold PBS containing 1 mM phenylmethylsulfonyl fluoride
(PMSF) and then with a buffer containing 50 mM HEPES (pH 7.5), 150 mM
NaCl, 25 mM b-glycerophosphate, 25 mM NaF, 5 mM EGTA, 1 mM EDTA,
15 mM pyrophosphate, 2 mM sodium orthovanadate, 10 mM sodiummolyb-
date, leupeptin (10 mg/ml), aprotinin (1 0mg/ml), and 1 mM PMSF. Cells were
extracted in the same buffer containing 1% Nonidet-P40. Lysates were then
clarified by centrifugation and frozen at 280C. Protein concentrations were
determined using the Bio-Rad protein assay kit.
Immunochemical techniques and immunoblot quantification
Immunoblot analyses were performed using 20 mg cleared cell lysates. This
material was electrophoretically resolved on denaturing sodium doedecyl
sulfate (SDS)-polyacrylamide gels (4%–12%), transferred to polyvinylidene
difluoride membranes (PVDF; Millipore), and probed with specific antisera
using standard techniques. Bound antibodies on immunoblots were de-
tected by either chemiluminescent (ECL, Pierce) or infrared (LiCor, Odyssey)
imaging. Images were recorded as TIFF files for quantitation (see below). Im-
munoblots analysis of each protein was performed at least twice in all cases
to ensure reproducibility. Antibodies used in these western analysis are
described in Table S7.
Protein quantification
Protein levels were measured by quantifying emitted chemiluminescence or
infrared radiation recorded from labeled antibodies using Scion Image
(http://www.scioncorp.com/) or Odyssey software (http://www.licor.com/).
For each protein, the blots were made for 4 sets of 11 cell lines, each setCANCER CELL DECEMBER 2006
A R T I C L Eincluding the same pair (SKBR3 and MCF12A) to permit intensity normaliza-
tion across sets. A basicmultiplicative normalization was carried out by fitting
a linear mixed-effects model to log intensity values and adjusting within
each set to equalize the log intensities of the pair of reference cell lines across
the sets.
Boyden chamber invasion assays
Assays were performed in modified Boyden chambers with 8 mm pore filter
inserts for 24-well plates (BD Bioscience). Filters were coated with 12.5 ml
of ice-cold 20% basement membrane extract (Matrigel, BD Bioscience).
Epithelial cells were added to the upper chamber in 300 ml of serum-free
medium. For the invasion assay, 7.5 3 104 cells were seeded on the 20%
Matrigel-coated filters and incubated for 24 hr. The lower chamber was filled
with 300 ml of full medium. After incubation, epithelial cells on the underside of
the filter were fixed with 2.5% glutaraldehyde in PBS and stained with 0.5%
toluidine blue in 2%Na2CO3. Cells that remained in the gel or attached to the
upper side of the filter were removed with cotton tips. Cells on the underside
of the filter were counted using light microscopy. Assays were performed in
triplicate or quadruplicate. The results were expressed as an average 6 one
standard deviation.
Comparative genomic hybridization
Each sample was analyzed using Scanning and OncoBAC arrays. Scanning
arrays were comprised of 2464 BACs selected at approximately megabase
intervals along the genome as described previously (Hodgson et al., 2001;
Snijders et al., 2001). OncoBAC arrays were comprised of 1860 P1, PAC,
or BAC clones. About three-quarters of the clones on the OncoBAC arrays
contained genes and STSs implicated in cancer development or progres-
sion. All clones were printed in quadruplicate. Data presented are the union
of these two data sets. Arrays were prepared as described (Fridlyand et al.,
2006; Snijders et al., 2001). Briefly, we random-prime labeled 500w1000 ng
of test (cell line) and reference (normal female, Promega) genomic DNA with
CY3-dUTP and CY5-dUTP (Amersham), respectively, using Bioprime kit (In-
vitrogen). Labeled DNA samples were coprecipitated with 50 mg of human
Cot-1 DNA (Invitrogen), denatured, hybridized to BAC arrays for 48–72 hr,
washed, and counterstained with DAPI. Most of the data presented are
based on the results of a single hybridization. Repeated measurements of
genome aberrations in other experiments show that the results are highly
reproducible.
Data processing
Array CGH data image analyses were performed as described previously
(Jain et al., 2002). In this process, an array probe was assigned a missing
value for an array if there were fewer than two valid replicates or the standard
deviation of the replicates exceeded 0.3. Array probes missing in more than
50% of samples in the OncoBAC or scanning array data sets were excluded
in the corresponding set. Array probes representing the sameDNA sequence
were averaged within each data set and then between the two data sets.
Finally, the two data sets were combined, and the array probes missing
in more than 25% of the samples, unmapped array probes, and probes
mapped to chromosome Y were eliminated. The final data set contained
2696 unique probes representing a resolution of 1 Mb.
Affymetrix microarray analysis
Total RNA was prepared from samples using Trizol reagent (GIBCO BRL Life
Technologies), and quality was assessed on the Agilent Bioanalyser 2100.
Preparation of in vitro transcription (IVT) products, oligonucleotide array
hybridization, and scanning were performed according to Affymetrix (Santa
Clara, California) protocols. In brief, 5 mg of total RNA from each breast can-
cer cell line and T7-linked oligo-dT primers were used for first-strand cDNA
synthesis. IVT reactions were performed to generate biotinylated cRNA
targets, which were chemically fragmented at 95C for 35 min. Fragmented
biotinylated cRNA (10 mg) was hybridized at 45C for 16 hr to Affymetrix high-
density oligonucleotide array human HG-U133A chip. The arrays were
washed and stained with streptavidin-phycoerythrin (SAPE; final concentra-
tion 10 mg/ml). Signal amplification was performed using a biotinylated anti-
streptavidin antibody. The array was scanned according to the manufac-
turer’s instructions (2001 Affymetrix Genechip Technical Manual). Scanned
images were inspected for the presence of obvious defects (artifacts or
scratches) on the array. Defective chips were excluded, and the sample
was reanalyzed.CANCER CELL DECEMBER 2006Data processing
Probe set based gene expressionmeasurements were generated fromquan-
tified Affymetrix image files (‘‘.CEL’’ files) using the RMA algorithm (Irizarry
et al., 2003) from the BioConductor (http://www.bioconductor.org/) tools
suite. All 51 CEL files were analyzed simultaneously, creating a data matrix
of probe sets by cell lines inwhich each value is the calculated log abundance
of each probe set gene for each cell line. Probe sets were annotated with Un-
igene annotations from the July 2003 mapping of the human genome (http://
genome.ucsc.edu/), resulting in 19,764 annotated probe sets representing
13,406 unique unigenes. Gene expression values were centered by subtract-
ing the mean value of each probe set across the cell line set from each mea-
sured value. The gene expression data were organized using hierarchical
clustering to facilitate visualization of commonalities and differences in
gene expression across the set of cell lines. These analyses were restricted
to the set of genes that showed substantial variation across the data set by
selecting all probe sets that had at least four measurements that varied by
more than Log2 1.89. This resulted in 1438 probe sets corresponding to
1213 unigenes. This variation restriction was arbitrary but did not affect the
outcome of the eventual analysis. Probe sets corresponding to the same
gene were down-weighted inversely proportional to their frequency prior to
clustering (Wouters et al., 2003). Agglomerative clustering (Eisen et al.,
1998) was applied to probe sets and cell lines using the uncentered Pear-
son’s correlations. Resulting clusters were visualized using Java TreeView
(Saldanha, 2004). All expression data, array CGH data, and cluster files are
available at http://cancer.lbl.gov/breastcancer/data.php.
PAM analysis
Analysis was performed in R (http://www-stat.stanford.edu/%7Etibs/
PAM/Rdist/index.html) following the instructions therein (http://www-stat.
stanford.edu/%7Etibs/PAM/Rdist/doc/readme.html) (Tibshirani et al., 2002).
Three classifiers were defined (luminal, Basal A, and Basal B, as determined
from the hierarchical clustering of the cell line expression data). Classifier
training, crossvalidation, and calculation of false discovery rates were per-
formed, resulting in 396 genes identified at a threshold of 4.0. Subsequently,
a better threshold scaling was calculated, and a threshold of 2.8 chosen
based on the false discovery rate resulted in the 305 gene classifier.
Association of copy number with expression
The presence of an overall dosage effect was assessed by subdividing each
chromosomal arm into nonoverlapping 20 Mb bins and computing the aver-
age of cross-Pearson’s-correlations for all gene-clone pairs that mapped to
that bin. The average cross-correlations between clones and genesmapping
to the same bin were significantly higher than those between clones and
genes mapping to unlinked bins (p value < 10216, Wilcoxon rank sum test).
Pearson’s correlations and corresponding p values between expression level
and copy number also were calculated for each gene. Each gene was as-
signed an observed copy number of the nearest mapped BAC array probe.
Eighty percent of genes had a nearest clone within 1 Mbp, and 50% had
a clone within 400 kb. Correlation between expression and copy number
was only computed for the mapped genes whose absolute assigned copy
number exceeded 0.2 in at least five samples. This was done to avoid spuri-
ous correlations in the absence of real copy number changes. The Holm p
value adjustment was applied to correct for multiple testing. Genes with an
adjusted p value < 0.05 were considered to have expression levels that
were significantly affected by gene dosage. This corresponded to aminimum
Pearson’s correlation of 0.44.
Microarray data
The raw data for expression profiling are available at ArrayExpress (http://
www.ebi.ac.uk/arrayexpress/) with accession number E-TABM-157.
All expression data, array CGH data, and cluster files are also
available at the CaBIG repository (http://caarraydb.nci.nih.gov/caarray/
publicExperimentDetailAction.do?expId=1015897590151581), at http://
cancer.lbl.gov/breastcancer/data.php, and in the Supplemental Data.
Supplemental data
The Supplemental Data include four supplemental figures and seven supple-
mental tables and can be found with this article online at http://www.
cancercell.org/cgi/content/full/10/6/515/DC1/.525
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